Introduction
It is well established that defective processes of cellular homeostasis, like functions involved in DNA repair and genomic stability, result in a predisposition toward malignant transformation (Hanahan and Weinberg, 2000) . Dysregulation of protein synthesis, however, is only recently beginning to receive attention as a major step in malignant progression. A decade ago, studies aimed at understanding the regulation and function of eIF-4E culminated in the unexpected finding that a moderate overexpression of this translation initiation factor results in dramatic phenotypic changes, including rapid proliferation, suppression of apoptosis and malignant transformation. Conversely, the tumorigenic properties of cancer cells can be strongly inhibited by antisense RNA-mediated reduction of eIF-4E expression or by overexpression of the inhibitory eIF-4E binding proteins, the 4E-BPs. eIF-4E expression was subsequently found to be elevated in carcinomas of the breast, head and neck, bladder, cervical, lung and prostate, when compared with normal tissues and benign lesions. These data firmly implicate elevated eIF-4E expression in malignant progression.
Establishing a greater protein synthesis output may be critical for cancer cells to sustain rapid rates of cell division. However, analysis of cells transformed by eIF-4E revealed that the synthesis of only select proteins was greatly enhanced, while synthesis of most was only minimally increased. These studies therefore indicate that eIF-4E specifically stimulates translation of several oncogenic transcripts that, under normal cellular conditions, are translationally repressed. The concerted upregulation of these key malignancy-related proteins (e.g. vascular endothelial growth factor (VEGF), cyclin D1, matrix metalloprotease 9 (MMP-9)) may thereby enable tumor cells to over-ride normal growth constraints, stimulate angiogenesis, invade surrounding tissue, survive outside the original tissue and establish the autocrine stimulatory growth and survival signals necessary for the successful establishment of metastases. Thus, a major step in understanding the role of eIF-4E in malignancies will be to determine the spectrum of mRNAs that are particularly dependent on excess eIF-4E for efficient translation. This review will focus on the theoretical and experimental basis supporting a role for eIF-4E as a therapeutic target and a marker for tumor recurrence.
Protein synthesis and mRNA discrimination mRNA translation is hierarchical Protein synthesis plays a fundamental role in nearly every aspect of metabolism. It also constitutes a critical step in the control of gene expression , as mRNAs must be recruited for translation. The synthesis of each protein ultimately depends on the relative abundance of its mRNA and its intrinsic translatability, that is, the capacity of that particular mRNA to interact with components of the translation initiation machinery. This property of the translation initiation process establishes a hierarchy among the different mRNAs to be translated because the initiation capacity of protein synthesis is limiting. In eucaryotes, the flow of information from genes to proteins is too slow to accommodate rapid changes in the environment. Eucaryotes compensate for this problem by maintaining a pool of mRNAs that are not immediately utilized. Examples may include transcripts that encode growth factors that can be rapidly produced under conditions that require cells to re-enter cell division rapidly.
In metazoans, mRNAs vary over a 100-fold range in their translational efficiencies (Koch et al., 1980) . Moreover, their translation depends on the particular growth conditions of the cell. A theoretical treatment of mRNA competition (Lodish, 1974; Rhoads et al., 1993; Graff and Zimmer, 2003) postulates that the spectrum of translated mRNAs varies with the overall rate of protein synthesis. Weak mRNAs are outcompeted by strong mRNAs when the rate of translation initiation is reduced, as in quiescent cells (Baserga, 1990) , whereas weak and strong mRNAs are translated when protein synthesis becomes dysregulated, as is the case in many human and experimental cancers. A disproportionate number of mRNAs that would be characterized as weak (based on structural features explained later) are those encoding oncoproteins and growth/survival factors. Several of these genes also share the property of being cell-cycle regulated and, in turn, their protein products affect cell-cycle progression (Baserga, 1990; Graff and Zimmer, 2003) . These translationally regulated genes are listed in Table 1 .
Protein synthesis
Protein synthesis is energetically the most expensive process in the cell and, not surprisingly, translation rates are tightly regulated (reviewed in Rhoads et al., 1993; Rhoads, 1988) . In mammals, most of the regulation thus far discovered operates at the level of translation initiation, rather than elongation or termination. The initiation process comprises three steps: (1) formation of the 43S complex, composed of a 40S ribosomal subunit and the initiation factors eIF-2, eIF-3, Met-tRNA i and GTP; (2) formation of the 48S complex containing mRNA, which is mediated by the eIF-4 group of factors; and (3) joining of the 60S subunit to form the complete 80S complex. In most circumstances, the second step is rate limiting and, hence, a major point of regulation. This step is also a point of discrimination, since one particular mRNA is selected from the untranslated pool and recruited to the ribosomes. As mentioned above, this process is mediated by the eIF4 group of factors, for which eIF-4E is rate-limiting (Hiremath et al., 1985; Duncan et al., 1987) . Evidence supporting the role for eIF-4E as rate-limiting was obtained experimentally with the application of antisense RNA technology. Antisense RNA-mediated reduction in eIF-4E expression suppressed protein synthesis rates and the spectrum of expressed proteins in direct proportion to the level of eIF-4E (De Benedetti et al., 1991) .
Regulating eIF-4E function and the activity of the eIF-4F complex
Under normal cellular conditions, eIF-4E is bound by the inhibitory 4EBPs, which sequester eIF-4E from interaction with eIF-4G, the scaffolding protein of the eIF-4F translation initiation complex. Upon mitogenic stimulation, the 4EBPs become phosphorylated at multiple sites as a consequence of both the ras-ERK and PI3 kinase/AKT signaling pathways (Gingras et al., 2001 ; see Figure 1 ). These phosphorylation events dislodge the 4EBPs from eIF-4E, thereby liberating eIF-4E and enabling eIF-4E to deliver mRNAs effectively to the eIF-4F complex. Once bound to the scaffolding protein eIF-4G, eIF-4E may become phosphorylated at ser209 by the kinase MNK. This phosphorylation event may play a key regulatory role for eIF-4E cap binding, although there is controversy as 
Paradigm of strong and weak mRNAs
By specifically binding the 5 0 -terminal, 7-methylguanosine-containing cap of an mRNA, eIF-4E, following release from the 4EBPs, can deliver that mRNA to the eIF-4F complex. The eIF-4F complex then scans 5 0 -3 0 unwinding secondary structure in the 5 0 -untranslated region (5 0 -UTR) of the mRNA to reveal the initiation codon, trigger ribosome engagement and facilitate translation of that mRNA (Rhoads, 1988) . The abundance of the active eIF-4F complex is normally limiting due to the limited expression of eIF-4E as well as its binding to the inhibitory 4EBPs. As such, cellular mRNAs must compete with each other for access to the eIF-4F complex and for subsequent delivery to the ribosomes. The short, unstructured 5 0 -UTRs of most cellular mRNAs (e.g. housekeeping genes) enable the eIF-4F complex to scan readily for the translation initiation codon. Therefore, these strong mRNAs are efficiently translated, even when the active eIF-4F complex is limiting. By contrast, the lengthy, G þ Crich, highly structured 5 0 -UTRs, typical of growth factor and proto-oncogene mRNAs (i.e. weak mRNAs), encumber efficient scanning and start codon recognition. Consequently, these mRNAs are inefficiently translated, especially when the active eIF-4F complex is limiting (Pelletier and Sonenberg, 1987; Kozak, 1991; Thach, 1992; Rhoads, 1993; Geballe and Morris, 1994; Morley, 1994; Gingras et al., 1999; Zimmer et al., 2000; Graff and Zimmer, 2003) . Figure 2 graphically depicts this hypothesis, showing the relative translational efficiency of a strong and a weak mRNA as a function of free eIF-4E levels (i.e. active eIF-4F complex). Translation of strong mRNAs (e.g. those encoding housekeeping proteins such as b-actin) will quickly reach a maximum in the presence of low levels of free eIF-4E, even in quiescent cells. Weak mRNAs are poorly translated when free eIF-4E is limiting. With increased free eIF-4E (i.e. increased active eIF-4F), the translation of these weak mRNAs (e.g. growth regulators) is disproportionately enhanced. Representative structures for the 5 0 -UTRs of a strong mRNA (b-actin) and a weak mRNA (VEGF) are inset (Figure 2 ). The levels of free eIF-4E can be increased substantially by one or all of the following mechanisms: (1) increased eIF-4E expression; (2) decreased 4EBP expression; or (3) increased 4EBP phosphorylation resulting from hyperactivation of intracellular signaling pathways. Cancer cells routinely show activation of the signaling pathways that phosphorylate 4EBPs and may also reduce expression of the 4EBPs (reviewed by Huang et al., 2003) . In addition, as discussed more extensively below, cancer cells frequently display increased eIF-4E expression as well (Graff and Zimmer, 2003) .
Persistently high levels of free eIF-4E would selectively and disproportionately enhance the translation of weak mRNAs. As these weak mRNAs almost universally encode growth regulatory proteins, the concerted upregulation of these gene products may profoundly influence the biology of these cells, enabling tumorigenesis and ultimately metastatic progression. A wealth of experimental evidence now supports the notion that increasing levels of free eIF-4E preferentially enhances (Lodish, 1974) , it was developed here from theoretical considerations and experimental observations (De Benedetti and Rhoads, 1990; Rhoads et al., 1993; Graff and Zimmer, 2003) . The products of weak mRNAs become selectively increased with higher free eIF-4E, which results in increased active eIF-4F complex. Disproportionately increased translation of these weak mRNAs would increase with malignant progression in relation to increased free eIF-4E. Representative structures for the 5 0 -UTR of the b-actin, a strong mRNA and VEGF, a weak mRNA, are depicted. These structures were generated with the Zucker m-fold RNA structure program Figure 1 Cell signaling pathways that activate the eIF-4F complex. The PI3 kinase/AKT and ras-ERK signaling pathways can liberate eIF-4E from the inhibitory binding proteins, the 4EBPs. Upon release, eIF-4E is free to engage and thereby activate the eIF-4F complex, recruiting mRNAs to this complex and promoting ribosome loading on the mRNAs. Enhanced translation of growth factor mRNAs, which are particularly dependent on the activity of the eIF-4F complex, can then in turn stimulate these same signaling pathways, amplifying the activity of the ras-ERK and PI3 kinase/AKT pathways (reviewed in Graff, 2002; Graff and Zimmer, 2003) eIF-4E in oncogenesis and metastasis AD Benedetti and JR Graff the translation of the weak mRNAs driving transformation and malignancy (Graff and Zimmer, 2003) .
Role of eIF-4E in malignancy
Altering eIF-4E expression profoundly impacts transformation, tumorigenesis and metastasis Our understanding of the link of translational control with oncogenesis was initially prompted by the effects of eIF-4E overexpression in tissue culture. Overexpression of eIF-4E resulted in cellular transformation and tumorigenesis in the immortalized but nontransformed cell lines, NIH3T3, CREF or MM3MG (De Benedetti and Rhoads, 1990; De Benedetti et al., 1994; LazarisKaratzas et al., 1990; Li et al., 2001) . eIF-4E also acts as a potent enhancer of transformation in cooperation with v-myc or E1A (Lazaris- and Max . It was subsequently discovered that eIF-4E expression is elevated in many malignant cell lines (Miyagi et al., 1995; Anthony et al., 1996) . In CREF cells, eIF-4E overexpression not only induced transformation and tumor formation but also induced metastatic capacity. Interestingly, eIF-4E-transfected CREF cells harvested from spontaneous lung metastases showed even greater eIF-4E expression, suggesting that the process of metastasis further selected for eIF-4E overexpression (Zimmer et al., 2000) .
Further evidence supporting a role for eIF-4E in malignancy has been provided by studies wherein eIF-4E expression was suppressed by antisense RNA expression or eIF-4E function was blocked by the expression of 4EBPs. Ectopic expression of 4EBP1 reverted the transformed and tumorigenic phenotype of cells transformed by eIF-4E or v-src (Rousseau et al., 1996) . Expression of antisense RNA to eIF-4E in HeLa cells suppressed proliferation and altered cellular morphology (De Benedetti et al., 1991) . Antisense RNA-mediated reduction of eIF-4E by B60% in rastransformed CREF cells suppressed soft-agar colonization as well as tumor formation and growth (RinkerSchaeffer et al., 1993) . Moreover, the ability of these cells to invade surrounding normal tissues and to metastasize was profoundly suppressed (Graff et al., 1995) . Similarly, in human breast and head and neck cancer cell lines, antisense-RNA-mediated reduction of eIF-4E suppressed tumor formation and angiogenesis (Nathan et al., 1997a, b; DeFatta et al., 2000) .
eIF-4E regulates the translation of malignancy-related mRNAs
As depicted in Figure 2 , altering the levels of free eIF-4E would be expected to influence selectively the translation of weak mRNAs -mRNAs with lengthy, G þ C-rich 5 0 -UTRs. These mRNAs largely encode proto-oncoproteins, angiogenesis factors and other growth and survival factors critical for malignancy. Translation of model mRNAs engineered to have excess secondary structure in their 5 0 -UTRs (i.e. model weak mRNAs) was specifically stimulated in cells overexpressing eIF-4E (Koromilas et al., 1992; Kevil et al., 1995) . Further work has now revealed that eIF-4E specifically controls the translation of endogenous mRNAs whose protein products are well recognized to contribute to malignancy. These mRNAs encode proto-oncoproteins such as c-myc, cyclin D1 and ornithine decarboxylase (ODC), angiogenesis factors such as FGF-2 and VEGF and degradative enzymes that enable tumor invasiveness such as MMP-9.
Translational control of proto-oncoproteins C-myc, one of the best-studied oncogenes (Battey et al., 1983) , is known to be translationally regulated presumably via its lengthy G þ C-rich 5 0 -UTR (Saito et al., 1983) . When cloned upstream of a heterologous reporter gene, the c-myc 5 0 -UTR conferred translational suppression (Darveau et al., 1985) . Consistent with these findings, overexpression of eIF-4E in CHO or CREF cells yielded increased c-Myc expression .
Cyclin D1, which is required to drive cells through the G1/S-phase transition (Stacey, 2003) , is regulated by eIF-4E as well. In NIH3T3 cells overexpressing eIF-4E, cyclin D1 translation was specifically stimulated (Rosenwald et al., 1993) . Further investigation revealed that eIF-4E stimulated the nucleocytoplasmic transport of cyclin D1MRNA, and thereby enhanced cyclin D1 translation (Rosenwald et al., 1995; Rousseau et al., 1996) .
ODC, the rate-limiting enzyme for polyamine biosynthesis, is recognized as a proto-oncogene (Auvinen et al., 1997) . The translational regulation of ODC has been attributed to its lengthy G þ C-rich 5 0 -UTR, which can confer translational suppression upon heterologous reporter genes (Manzella et al., 1991) . Overexpression of eIF-4E in NIH 3T3 cells relieved this translational suppression, thereby resulting in increased ODC translation, an event critical for eIF-4E-induced transformation Shantz et al., 1996) . Depletion of eIF-4E with antisense RNA in rastransformed CREF cells specifically suppressed ODC translation in concert with a reversion of the malignant phenotype (Graff et al., 1997) .
eIF-4E and the translation regulation of angiogenesis factors
Further progress on the oncogenic properties of eIF-4E came with the observation that conditioned media from cells transformed with eIF-4E are mitogenic, in particular, to vascular endothelial cells. Basic fibroblast growth factor (FGF-2) acts as a potent mitogen for a variety of mesoectodermal lineages (Gospodarowicz et al., 1987; Wellstein et al., 1990; Wellstein and Lippman, 1991) . FGF-2 is also a powerful angiogenic factor involved in tumor vascularization (Klagsbrun et al., 1986; Folkman and Klagsbrun, 1987) . The importance of FGF-2 to breast cancer became apparent with the discovery that the mouse mammary tumor virus integrates preferentially at a genetic locus (int-2) eIF-4E in oncogenesis and metastasis AD Benedetti and JR Graff that encodes FGF (Smith et al., 1988) . A high level of FGF-2 in breast carcinomas is considered to be a poor prognostic determinant (see, for a review, Wellstein et al., 1990; Wellstein and Lippman, 1991) . Although an increase in FGF-2 is prevalent in invasive breast carcinomas, amplification at the gene or mRNA level is found in only 10-15% of the cases (Theillet et al., 1989) , suggesting that the mechanism of upregulation is post-transcriptional. FGF-2 expression was dramatically increased in CHO cells overexpressing eIF-4E (CHO-4E) compared to control cells (Kevil et al., 1995) . We further demonstrated that the increase was at the level of translation by in vivo and in vitro experiments and depended on the level of eIF-4E. Importantly, elevated eIF-4E expression correlated directly with increased expression of FGF-2 in tumor biopsies (Nathan et al., 1997a) . VEGF/vascular permeability factor is perhaps the most specific and potent cytokine for vascular endothelia (Leung et al., 1989) . As mentioned above, conditioned medium from CHO-4E cells was strongly mitogenic for human umbilical vein endothelial cell cultures. Clearance with antibodies against FGF-2 only partially compromised this activity, indicating that additional factor(s) may be overproduced. VEGF was the next most logical candidate and, in fact, it was markedly overexpressed (Kevil et al., 1996) . The increase was almost exclusively translational. In these CHO-4E cells, VEGF mRNA partitioned primarily to the heavy polysome region, in contrast to its distribution on the small polysomes in control cells.
In primary human tumors, elevated eIF-4E expression has been correlated with increased expression of FGF-2 (Nathan et al., 1997a) and VEGF (Scott et al., 1998) . Furthermore, the level of VEGF mRNA correlates strongly with the level of eIF-4E mRNA (P ¼ 0.0002; Scott et al., 1998) . As mentioned above, FGF-2 and VEGF may be the two most powerful mitogens for vascular endothelia and they work synergistically. Evidence for elevated eIF-4E in angiogenesis and the progression of breast carcinomas was obtained with experiments in which the level of eIF-4E was suppressed with antisense RNA technology. When the level of eIF-4E was reduced to near normal in MDA-435 human breast cancer cells (Nathan et al., 1997a) or in PC-3 human prostate cancer cells (Williams et al., 1998) , their angiogenic and tumorigenic properties were crippled. The viability and tissue culture properties, including the capacity to grow in soft agar, of 435AS and PC3AS (i.e. antisense RNA to eIF-4E) cells were otherwise unaffected.
Translational control of degradative enzymes
Various types of collagenases and fibrinolytic enzymes are critical for remodeling of the stromal layers surrounding the tumors, for subsequent recruitment of supporting vasculature, for development of a complex inflammatory response against the tumor cells (that has both beneficial and detrimental effects) and for tumor metastasis. Reduction of eIF-4E with antisense RNA in ras-transformed CREF cells inhibited the expression of the 92 kDa collagenase, MMP-9, correlating with reduced metastatic capacity in these cells (Graff et al., 1995) . A subsequent study has now shown that MMP-9 is translationally controlled in malignant murine prostatic carcinoma cells. MMP-9 mRNA levels are nearly identical in aggressive, highly malignant murine prostatic carcinoma cells and in their less aggressive counterparts, yet MMP-9 protein expression is markedly upregulated only in the aggressive variants. In these cells, MMP-9 mRNA is specifically shifted into polysomal fractions (Jiang and Muschel, 2002) .
Heparanase overexpression has been repeatedly linked to the stimulation of angiogenesis and to metastasis (Simizu et al., 2003) . Antisense oligonucleotides against the eIF-4E mRNA strongly suppressed the expression of heparanase, as well as the invasive properties of the colon adenocarcinoma cell line LS-174T (Yang et al., 2003) , suggesting that heparanase overexpression is dependent on eIF-4E function.
Cap-independent translation
It is important to note that translation of the FGF-2, VEGF and c-myc mRNAs that we have found to be enhanced in eIF-4E-overexpressing cells can also be driven by an internal ribosome entry site, or IRES (Vagner et al., 1995; Stein et al., 1998; Stonely et al., 1998) . As such, their translation may occur even in the presence of limiting free eIF-4E (i.e. cap independent) under special conditions. For example, translation of cmyc mRNA can occur at the M phase of the cell cycle where cap-dependent translation is inhibited (Pyronnet et al., 2000) . However, another study has shown that the mechanism of c-myc translation is more consistent with shunting (Carter et al., 1999) , a form of initiation that requires cap-proximal entry of ribosomes and eIF-4E. It is not currently clear what contribution IRES-dependent translation may have on the increased expression of these potent growth-regulatory molecules in cancer cells.
Elevated expression of eIF-4E is common in human carcinomas

Breast cancers
Elevated eIF-4E expression was initially researched in breast cancer. The basal level of eIF-4E in normal breast tissue is low, making the abnormally elevated eIF-4E expression in carcinomas very evident. We and other groups have found that in breast cancer, eIF-4E is elevated three-to 30-fold above normal breast and benign lesions, and it is a ubiquitous feature of breast carcinomas (Kerekatte et al., 1995; Scott et al., 1998) . This elevation is already evident in about 50% of ductal carcinoma in situ biopsies, the earliest stage of clearly identifiable breast cancer (DeFatta et al., 1999) . Benjamin Li and co-workers analysed clinical data for eIF-4E expression in relation to disease parameters and revealed that a X7-fold elevation in eIF-4E expression eIF-4E in oncogenesis and metastasis AD Benedetti and JR Graff was a strong, independent prognostic indicator of recurrence and death from breast cancer (Li et al., 1997 (Li et al., , 1998 . In addition, in a prospective study of 191 women with stage I-III breast carcinoma, the subset of patients with X14 elevated eIF-4E expression had a 7.2-fold greater risk of cancer recurrence (P ¼ 0.002; Li et al., 2002) . In these studies, eIF-4E expression levels were assessed by Western blotting of tumor-enriched fresh tissue. This enabled us to better relate the levels of eIF-4E overexpression to patient outcome. Immunohistochemistry (IHC) evaluation also routinely demonstrated eIF-4E overexpression, but could not reveal the precise level to which eIF-4E is overexpressed.
The mechanism of eIF-4E overexpression is still under investigation. We have found increased eIF-4E expression during hypoxic conditions by analysis of confined breast biopsies using IHC (DeFatta et al., 1999) . In human and experimental tumors, the development of hypoxia is a common event, which stimulates angiogenesis and is thought to promote tumor progression ultimately (Zhong et al., 1999) . As such, the hypoxia that accompanies tumor growth may stimulate eIF-4E expression. Transcription of eIF-4E can also be regulated by the potent proto-oncoprotein myc (Jones et al., 1996) , which is frequently upregulated in a wide variety of tumor types. Interestingly, eIF-4E also enhances myc translation. It is plausible that a positive stimulatory loop exists wherein myc stimulates eIF-4E transcription, which, in turn, stimulates myc translation, thereby perpetuating positive growth and survival signals.
Head and neck cancers
Head and neck squamous cell carcinomas (HNSCC) have a high local recurrence rate due in part to incomplete tumor resection. In fact, the high lethality of this type of cancer is not due to metastasis, but due to local recurrence in most cases. Therefore, complete resection of the tumor is critically important for survival. Incomplete excision will almost invariably result in rapid recurrence and death from tumor burden. Margins are determined during surgery by histopathologic analysis on frozen sections. Unfortunately, benign/ atypical dysplasia and ulcerations are very common in the oral cavity of these patients, making it difficult to distinguish between malignant and preneoplastic lesions. To bolster this critical distinction, molecular markers of malignancy would be enormously beneficial. eIF-4E expression is low in benign lesions, such as polyps and leukoplakia, but it is clearly elevated in HNSCC. The presence of as little as 5% eIF-4E-positive cells present at the surgical margins (as revealed by IHC) was sufficient to predict local recurrence in two-thirds of the patients with recurrence within 2 years (Nathan et al., 1997b; Franklin et al., 1999) .
Colorectal cancers
Colon carcinogenesis has become one of the best-studied models of cancer progression, as premalignant lesions (polyps and adenomatous lesions) can be recovered in adjacent biopsies, frequently in a spatial pattern that is indicative of disease progression. Upregulation of eIF-4E was shown to be an early event in colon carcinogenesis . In this study, expression of eIF-4E was directly related to increased expression of the cyclin D1 protein. In a larger study, eIF-4E expression was found to be elevated significantly in colorectal carcinomas relative to normal colonic tissue and was strongly associated with the histologic type of the lesion (Berkel et al., 2001) .
Bladder cancers eIF-4E expression was found to be elevated in bladder tumors relative to normal bladder tissue (Po0.0001). Furthermore, eIF-4E expression correlated with increased VEGF protein: mRNA ratios, further supporting the link between eIF-4E and VEGF expression. In superficial tumors, high levels of eIF-4E expression were associated with a poor prognosis and reduced progression-free survival (P ¼ 0.04, Cox's proportional-hazards model). Furthermore, eIF-4E expression was highest in invasive cancers (Crew et al., 2000) . This study implicates enhanced eIF-4E expression in the regulation of VEGF expression and the malignant progression of human bladder cancers.
Prostatic adenocarcinoma
Williams and co-workers carried out a retrospective study of 123 human prostate tissue samples (normal, BPH, high-grade PIN, organ-confined tumors and lymph node metastases), including 56 from AfricanAmerican men, to assess the frequency of eIF-4E overexpression in prostate tissues and its relationship with angiogenesis. eIF-4E overexpression in tumors correlated with elevated levels of VEGF and higher microvessel density (MVD). Interestingly, elevated MVD was significantly associated with eIF-4E positivity only in tumors from African-American men, suggesting that race or ethnicity may have a biological influence on the angiogenic process (Williams, personal communication ). An independent study of 100 prostate specimens also noted increased eIF-4E expression that was specifically associated with advanced disease. eIF-4E expression was most dramatically upregulated in prostate cancers with a Gleason score 47. Importantly, elevated eIF-4E expression was unrelated to the proliferative index of the tissue, suggesting that increased eIF-4E expression is qualitatively related to advanced disease and does not simply reflect the enhanced proliferative status of the cancer (Graff and Carter, unpublished data) .
Lung cancers
eIF-4E expression in bronchial adenocarcinomas (but not squamous cell carcinomas) is three-to eight-fold higher than in the normal lung (Rosenwald et al., 2001) . In an independent study of adenocarcinomas of the eIF-4E in oncogenesis and metastasis AD Benedetti and JR Graff peripheral lung, eIF-4E was found to be elevated by up to seven fold relative to normal lung tissue and was specifically associated with histological grade and invasiveness of the tumor (Seki et al., 2002) . These studies implicate enhanced eIF-4E expression in the development and progression of lung cancers.
Cervical cancers
Cervical carcinoma is one of the most common cancers in women and is generally associated with human papilloma virus infection. Examination of eIF-4E expression by IHC in cervical dysplasia and carcinomas revealed a significant elevation when compared to normal cervical tissue. Thus, the presence of elevated eIF-4E in atypical cervical specimens may mark an early stage of cancer development in the cervix, suggesting that elevated eIF-4E expression may contribute to cervical carcinoma development (Mathews-Greer et al., 2002) .
Lymphomas
The expression of eIF-4E is elevated also in nonHodgkin's lymphomas and correlates with the aggressiveness of these lesions .
eIF-4E influences apoptosis and drug resistance
The balance between growth, quiescence and programmed death (apoptosis) is a delicate process required for the homeostasis of the organism that is accomplished by the orchestrated expression of survival (e.g. Bcl-2) and proapoptotic factors, like TNF and FasL (Nagata, 1997) . This delicate balance is disrupted in tumors such that proliferative rates exceed rates of cell death. As a consequence, the tumors show a net gain in cell number. As discussed previously, eIF-4E can enhance the translation of potent growth stimulatory proteins like c-myc and cyclin D1. eIF-4E can also act as a potent survival factor for serum-deprived cells, or for those with deregulated expression of myc or the ras oncogene (Polunovsky et al., 1996 Tan et al., 2000; Li et al., 2003) . eIF-4E overexpression has also been shown to impart radioresistance. Overexpression of eIF-4E may impart this phenotype by translationally upregulating expression of the Tousled-like protein kinase, TLK1B. TLK1B protects cells from radiation-or doxorubicin-induced death by mediating changes in chromatin structure through phosphorylation of histone H3 (Li et al., 2001) and the histone H3 chaperone, Asf1 (Sillje and Nigg, 2001 ).
Role of eIF-4E in metastatic progression
The metastatic phenotype is extremely complex requiring the metastasizing tumor cells to hurdle numerous, divergent challenges. To establish a successful metastatic colony, a tumor cell must induce angiogenesis, which enables continuous tumor growth and provides access to the vasculature. The tumor cell must also dislodge from the primary tumor site, break down and penetrate surrounding normal tissue, enter the blood or lymphatic circulation, survive within that circulation and exit at a site distal to the primary tumor site. Challenged by a different growth factor milieu in the tissue of the metastatic site, a metastasizing tumor cell must be able to attract a new blood supply and to generate the necessary growth and survival factors to support the successful establishment of a metastatic colony. This shift towards growth factor autonomy is essential for the successful establishment of metastases. Indeed, although many tumor cells are able to break from the primary tumor, enter the circulation and reseed at a distal site, only a very few will be able to establish a metastatic colony successfully (Shevde and Welch, 2003) .
Enhanced eIF-4E function can stimulate autocrine growth factor signaling. eIF-4E expression stimulated expression of activin, a member of the tumor growth factor b family, which in turn stimulated mesodermal development in Xenopus oocytes (Klein and Melton, 1994) . Overexpression of eIF-4E in NIH3T3 cells induced transformation, in part, by establishing an autocrine growth stimulatory loop that triggered signaling through the ras-MAP kinase pathway (LazarisKaratzas et al., 1992) . Similarly, overexpression of eIF-4E in CREF cells triggered signaling through the ERK pathway (Zimmer et al., 2000) . These data indicate that enhanced eIF-4E function can play a significant role in the acquisition of growth factor autonomy -a critical phenotype necessary for the successful establishment of metastases (Graff and Zimmer, 2003) . Indeed, enhanced eIF-4E function has been linked to metastasis in both experimental tumor systems and in human disease.
As mentioned previously, reduction of eIF-4E by antisense RNA suppressed the ability of ras-transformed CREF cells to metastasize to the lungs in an experimental metastasis assay. In this study, the few lung metastases that did form regained normal levels of eIF-4E expression, indicating that the successful establishment of metastases selected for cells with greater levels of eIF-4E expression (Graff et al., 1995) . CREF cells transformed by ectopic overexpression of eIF-4E were capable of forming both spontaneous and experimental metastases (Zimmer et al., 2000) . The metastatic colonies formed routinely showed even higher eIF-4E expression levels than that of the parental, transfected cells (Zimmer et al., 2000) . Again, these data suggest that progression to metastases involved selection for increased eIF-4E expression.
Inhibiting eIF-4E function by blocking the signaling cascades that release eIF-4E from 4EBPs also profoundly suppresses metastasis. The macrolide antibiotic rapamycin, which suppresses mTOR activity and thereby prevents the release of 4EBPs from eIF-4E (Figure 1) , dramatically suppressed the capacity of murine colon tumor cells to grow as experimental liver metastases (Guba et al., 2002) . Rapamycin treatment also prevents pulmonary metastasis of human renal cell carcinoma cells (Luan et al., 2003) .
Recently, transcriptional profiling of metastatic human solid tumors revealed a molecular signature for eIF-4E in oncogenesis and metastasis AD Benedetti and JR Graff metastasis. Expression of nine genes was routinely decreased across this diverse panel of solid tumor metastases, whereas eight genes were found to be consistently upregulated. eIF-4E was identified as one of these eight genes. Consequently, enhanced expression of eIF-4E serves as part of a molecular signature for human solid tumor metastases (Ramaswamy et al., 2003) . Together, these data clearly support the notion that enhanced eIF-4E may play a role in metastatic progression and further buttress the notion that eIF-4E may represent an attractive therapeutic target for the treatment of human malignancy.
eIF-4E as a therapeutic target
Both human and experimental tumors commonly show a marked increase in the relative abundance of free eIF-4E resulting from persistent signaling through the PI-3 kinase/AKT/mTOR and ras-ERK pathways or from overexpression of eIF-4E directly. As evidenced by numerous studies in human and experimental tumors, blocking eIF-4E function may have a profound effect on malignancy. To date, a number of therapeutic approaches to targeting eIF-4E have been employed in preclinical models, including standard small molecule therapies, antisense RNA strategies and a novel gene therapy approach that utilizes the enhanced eIF-4E activity of tumor cells as an Achilles' heal to kill tumor cells selectively (reviewed in Graff, 2002; Graff and Zimmer, 2003) .
Rapamycin and its derivatives inhibit the kinase mTOR and thus prevent phosphorylation of 4E-BP and the subsequent release of 4EBP from eIF-4E. Consequently, rapamycin treatment prohibits eIF-4E from engaging and activating the eIF-4F complex. As mentioned above, treatment of murine colon carcinoma cells or human renal cell carcinoma cells with rapamycin suppresses metastasis (Guba et al., 2002; Luan et al., 2003) . Rapamycin treatment may be particularly effective in tumors lacking PTEN function, such as glioblastomas and prostate cancers (Podsypanina et al., 2001; Neshat et al., 2001) . Early phase clinical trials with the rapamycin derivative, CCI-779, have indicated that this approach may indeed be a promising therapy, even as a single agent, for cancer treatment (Hidalgo and Rowinsky, 2000; Peralba et al., 2003) .
The reduction of eIF-4E via expression of antisense RNA in epithelial and fibroblast tumor models suppressed malignancy in concert with diminished translation of potent malignancy-related molecules such as VEGF, FGF-2 and ODC Graff et al., 1995 Graff et al., , 1997 Nathan et al., 1997a; DeFatta et al., 2000) . Whether antisense oligonucleotides can prove similarly effective for cancer therapy remains to be fully explored. However, recent advances in the field have enabled antisense oligonucleotides directed to other cancer targets to progress into clinical trials for cancer (Tamm et al., 2001 , Holmlund et al., 1999 .
The increased eIF-4E function characteristic of tumor cells has provided a potential Achilles' heal that we have now exploited in a gene therapy approach. Metastatic murine breast cancer cells were injected into the tail vein to facilitate the formation of pulmonary metastases. Mice were subsequently injected with plasmids expressing thymidine kinase (TK) to facilitate the cytotoxic conversion of ganciclovir. Mice injected with plasmids encoding TK linked to the translationally repressive 5 0 -UTR showed reduced 490% reduction in pulmonary metastases. Importantly, these mice showed no evidence for systemic toxicity as the translationally suppressed TK was exclusively expressed only in the tumor tissue, where eIF-4E activity was highest. In contrast, the mice injected with the uncontrolled TK plasmid showed significant toxicity attributable to the expression of the TK protein in all tissues and, subsequently, the systemic cytotoxic conversion of ganciclovir (DeFatta et al., 2002a, b) .
Concluding remarks
Numerous studies have now implicated eIF-4E in tumor formation and metastatic progression. eIF-4E is overexpressed in a wide variety of human tumors and its overexpression has routinely been linked to parameters of disease progression (tumor recurrence, disease state, patient prognosis). Indeed, increased eIF-4E expression may be a particularly important tumor marker. In experimental tumor systems, eIF-4E alone has been shown to be sufficient not only to induce transformation and tumorigenesis but also to enable metastases. eIF-4E mediates these profound phenotypic changes by selectively enhancing the translation of a limited pool of mRNAs that code for proteins intimately involved in malignancy. These proteins promote cell survival, tumor formation and growth (c-myc, cyclin D1), angiogenesis (VEGF, FGF-2), invasion and metastasis (MMP-9, heparanase). As such, enhanced eIF-4E function can contribute to every aspect of malignant progression.
Future progress will be driven by a better understanding of the mechanism(s) by which free eIF-4E levels are increased in tumor cells and by a more complete identification of the mRNAs specifically stimulated by eIF-4E in tumor cells. For instance, the promoter of eIF-4E is regulated by c-Myc (Jones et al., 1996) , a cell-cycle regulator that is found elevated in a large proportion of human cancers. However, the regulation of eIF-4E expression is likely to be more complex. The gene encoding eIF-4E was fairly recently cloned in its entirety (Gao et al., 1998) , and the functional elements are not fully elucidated. Furthermore, the eIF-4E gene resides on 4q21-22, a region of the chromosome that is frequently amplified in prostate cancer of African-Americans (Cher et al., 1996) . Interestingly, trisomy of chromosome 4 with double minutes of chromosome 8, involving the c-myc locus, is one of the most frequent rearrangements found in AML (Reddy and Sulkova, 1997) . Examining the shifts in the distribution of mRNAs into polysomes in tumor cells where eIF-4E activity is increased will likely reveal novel translationally regulated target genes that contribute to transformation and metastasis. Understanding these eIF-4E in oncogenesis and metastasis AD Benedetti and JR Graff processes more fully may illuminate the potential of eIF-4E as a tumor marker and will facilitate the development of anticancer strategies targeting eIF-4E.
